ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1

NCT00140595 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

380

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large-Cell Lymphoma

Interventions

DRUG: rituximab
DRUG: doxorubicin
DRUG: cyclophosphamide

Sponsor

Lymphoma Study Association

Collaborators

[object Object]